Products Press Releases Partnering Careers Contact

Featured Post

Kye Pharmaceuticals Announces the Availability of Dyanavel® XR Tablets Across Canada for the Treatment of ADHD

June 8, 2026

September 25, 2023

Health Canada approves Quillivant® ER (extended release) oral suspension and chewable tablets for the treatment of ADHD.

June 1, 2023

Kye Pharmaceuticals Announces Commercial Availability of CORZYNA™ 1000 mg (ranolazine extended-release tablets)

July 14, 2022

Accrufer® New Drug Submission accepted by Health Canada

May 24, 2022

KYE Pharmaceuticals Announces John McKendry as President

March 21, 2022

KYE Pharmaceuticals Files Accrufer® New Drug Submission in Canada for the Treatment of Iron Deficiency

March 11, 2022

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®